Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Lifecore Biomedical, Inc.NASDAQ: LFCR

Net Income · Q3 FY2026 · quarter ended Mar 2026

Net income of -$14.98M in Q3 FY2026

Q3 FY2026 net income was -$14.98M. Trailing-twelve-month net income was -$34.09M. Over 3 fiscal years it compounded at -30.8% a year.

Context

  • Net income amounted to 30.0% of revenue in FY2025, up 20.7 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$16.71M (-56.8%) for the fiscal year ending May 2026, a step up from the -422.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.98M+88.0% QoQ
Last fiscal yearMay 2025
-$38.72M-422.3% YoY
LTMMar 2026
-$34.09M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-422.3%-56.8%+365.5 pp
3-year CAGR-30.8%-4.0%+26.8 pp
5-year CAGR-10.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(38.72M) USD
Year-over-year change
-422.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How LFCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Net income amounts to 25.2% of revenue for LFCR, versus a peer median of 90.4%.
LFCR Competitors
Net Income for LFCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$286.21M CAD-52.6%-50.8%91.6%
BIOABioAge Labs, Inc.LTM Mar 2026$89.93M USD+26.6%+26.6%871.8%
IMMPImmutep LimitedFY2025A$61.43M AUD+43.8%+24.0%1218.0%
ACBAurora Cannabis Inc.LTM Mar 2026CA$58.58M CAD-507.7%-39.5%18.8%
CVRXCVRx, Inc.LTM Mar 2026$52.66M USD+2.2%+8.8%89.1%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$51.99M USD+12.6%+8.9%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
SGHTSight Sciences, Inc.LTM Mar 2026$37.25M USD-24.6%-23.6%46.8%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$34.09M USD—-30.8%25.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$17.17M USD-26.3%-28.6%41.1%
Peer median (excluding LFCR) —+2.2%-14.2%90.4%

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Depreciation & Amortization19.87M18.06M13.18M7.95M8.03M
Deferred Income Tax(7.87M)(6.83M)357K163K0
Stock-Based Compensation3.36M2.61M3.61M6.2M10.16M
Change in Working Capital9.76M(3.1M)19.79M(3.7M)(4.7M)
Accounts Receivables5.78M(6.14M)10.82M(2.39M)(2.26M)
Inventory(2.82M)(2.18M)(14.81M)862K7.69M
Accounts Payables(5.98M)9.34M16.04M(6.68M)(1.67M)
Other Working Capital12.79M(4.13M)7.74M4.51M(8.45M)
Other Non-Cash Items23.65M83.38M45.19M(22.38M)25.02M
Operating Cash Flow16.47M(22.59M)(17.44M)257K(206K)
Capital Expenditures(25.22M)(29.94M)(21.48M)(18.4M)(13.42M)
Acquisitions (Net)073.5M16.67M07M
Purchases of Investments00000
Sales of Investments045.1M000
Other Investing Activities12.91M(8.7M)000
Investing Cash Flow(12.31M)79.96M(4.81M)(18.4M)(6.42M)
Debt Repayment7.47M(55.41M)3.12M2.17M(18.56M)
Common Stock Issued004.82M023.85M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(10.89M)(1.61M)(6.32M)5.34M1.13M
Financing Cash Flow(3.42M)(57.02M)39.7M7.51M6.42M
Effect of Forex Changes00000
Net Change in Cash742K348K17.45M(10.63M)(197K)
Free Cash Flow(8.75M)(52.53M)(38.92M)(18.14M)(13.62M)

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.